MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejps.2025.107002

Медицинская библиотека · European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025

Activation of SIRT1 by SRT1720 alleviates dyslipidemia, improves insulin sensitivity and exhibits liver-protective effects in diabetic rats on a high-fat diet: New insights into the SIRT1/Nrf2/NFκB signaling pathway.

Elmorsy Elsayed A, Elsisi Hossam A, Alkhamiss Abdullah S, Alsoqih Norah Suliman, Khodeir Mostafa M, Alsalloom Abdulaziz A, Almeman Ahmad A, Elghandour Sahar R, Nadwa Eman Hassan, Khalifa Amira Karam, Khaled Bahaa Eldin Ali, Ramadan Asmaa, Kamal Manal M, Alsaeed Thamir Saad, Alharbi Mariam S, Abdel-Moneim Abdel-Moneim Hafez, Ellethy Abousree T, Saber Sameh

СтатьяПеревод пока не подготовлен

Аннотация

Insulin resistance and diabetes are associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) conditions, which are distinguished by metabolic dysfunction, oxidative stress and inflammation. Sirtuin 1 (SIRT1), a NAD+-dependent deacetylase, is fundamental in regulating metabolic pathways, reducing inflammation, and improving antioxidant defenses. This is the first study to investigate the effects of SRT1720, a SIRT1 activator, in diabetic rats on a high-fat diet. SRT1720 significantly lowered fasting blood glucose and insulin levels and enhanced glucose tolerance and HOMA-IR and QUICKI scores, indicating increased insulin sensitivity. The treatment also reduced total cholesterol, triglycerides, and LDL levels, showing amelioration of dyslipidemia. Moreover, SRT1720 lowered markers of liver fibrosis, including TGF-β, TIMP-1, Col1a1, and hydroxyproline, and decreased inflammation by reducing NFκB activity and pro-inflammatory cytokines (TNF-α and IL-6). Furthermore, SRT1720 augmented Nrf2 activity and HO-1 levels. Consequently, the SRT1720's protective role improved liver function and histology and prolonged rats' survival. These functions were suppressed by the co-administration of the SIRT1 inhibitor EX527, confirming that the beneficial effects of SRT1720 are SIRT1-dependent. Correlation analyses uncovered that increased SIRT1 activity was strongly associated with decreased oxidative stress, inflammation, insulin resistance, and fibrosis markers. To conclude, our results find that SRT1720 represents a promising therapeutic strategy for managing Type 2 diabetes in NAFLD or NASH patients possibly through the modulation of the SIRT1/Nrf2/NFκB signaling pathwa. SRT1720 could potentially halt or reverse the progression of these conditions and associated complications and merits further investigations.

Для цитирования: Elmorsy Elsayed A, Elsisi Hossam A, Alkhamiss Abdullah S, Alsoqih Norah Suliman, Khodeir Mostafa M, Alsalloom Abdulaziz A, Almeman Ahmad A, Elghandour Sahar R, Nadwa Eman Hassan, Khalifa Amira Karam, Khaled Bahaa Eldin Ali, Ramadan Asmaa, Kamal Manal M, Alsaeed Thamir Saad, Alharbi Mariam S, Abdel-Moneim Abdel-Moneim Hafez, Ellethy Abousree T, Saber Sameh. Activation of SIRT1 by SRT1720 alleviates dyslipidemia, improves insulin sensitivity and exhibits liver-protective effects in diabetic rats on a high-fat diet: New insights into the SIRT1/Nrf2/NFκB signaling pathway.. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2025. DOI: 10.1016/j.ejps.2025.107002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.